GlaxoSmithKline (GSK) Posts Quarterly Earnings Results
GlaxoSmithKline (NYSE:GSK) issued its quarterly earnings data on Wednesday. The company reported $0.31 earnings per share (EPS) for the quarter, American Banking News reports. The company had revenue of $10.09 billion for the quarter, compared to the consensus estimate of $10.31 billion.
GlaxoSmithKline (NYSE:GSK) opened at 51.75 on Wednesday. GlaxoSmithKline has a 1-year low of $41.68 and a 1-year high of $54.00. The stock has a 50-day moving average of $51.55 and a 200-day moving average of $50.1. The company has a market cap of $125.4 billion and a price-to-earnings ratio of 19.69.
Several analysts have recently commented on the stock. Analysts at Credit Suisse downgraded shares of GlaxoSmithKline from a “neutral” rating to an “underperform” rating in a research note to investors on Thursday, October 10th. On a related note, analysts at Citigroup Inc. downgraded shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. Finally, analysts at Cowen and Company upgraded shares of GlaxoSmithKline from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, August 21st. Three analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $87.60.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.